{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:26:18Z","timestamp":1719447978705},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00108-024-01734-y","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T08:02:11Z","timestamp":1718870531000},"page":"664-671","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinale neuroendokrine Tumoren\u00a0\u2013 Update 2024","Gastrointestinal neuroendocrine tumors:  update 2024"],"prefix":"10.1007","volume":"65","author":[{"given":"Harald","family":"Lahner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"1734_CR1","unstructured":"WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine tumours, 2022, Vol.\u00a08. 5th\u00a0Edn. (International Agency for Research on Cancer). Lyon, France."},{"issue":"1","key":"1734_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi\u00a0G et\u00a0al (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33(1):115\u2013154","journal-title":"Endocr Pathol"},{"key":"1734_CR3","doi-asserted-by":"crossref","unstructured":"Hackeng WM, Brosens LAA, Dreijerink KMA (2023) Aggressive versus indolent insulinomas: new clinicopathological insights. Endocr Relat Cancer 30(5):e220321","DOI":"10.1530\/ERC-22-0321"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2023.03.024","volume":"186","author":"A Boileve","year":"2023","unstructured":"Boileve\u00a0A et\u00a0al (2023) Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data. Eur J Cancer 186:122\u2013132","journal-title":"Eur J Cancer"},{"issue":"2","key":"1734_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele\u00a0RC et\u00a0al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase\u00a01\u20132\u00a0trials. Lancet Oncol 21(2):271\u2013282","journal-title":"Lancet Oncol"},{"issue":"e13249","key":"1734_CR6","first-page":"3","volume":"35","author":"H Sorbye","year":"2023","unstructured":"Sorbye\u00a0H et\u00a0al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J\u00a0Neuroendocrinol 35 (3): e13249","journal-title":"J Neuroendocrinol"},{"issue":"e13146","key":"1734_CR7","first-page":"7","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg\u00a0S et\u00a0al (2022) European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J\u00a0Neuroendocrinol 34 (7): e13146","journal-title":"J Neuroendocrinol"},{"key":"1734_CR8","doi-asserted-by":"crossref","unstructured":"Levy S et al (2022) Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study. Cancers (Basel) 14(10):2361","DOI":"10.3390\/cancers14102361"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"p","author":"J Hofland","year":"2023","unstructured":"Hofland\u00a0J et\u00a0al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J\u00a035(8):e13318","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"1734_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amjsurg.2020.08.003","volume":"221","author":"A Sada","year":"2021","unstructured":"Sada\u00a0A et\u00a0al (2021) Comparison of benign and malignant insulinoma. Am J Surg 221(2):437\u2013447","journal-title":"Am J Surg"},{"key":"1734_CR11","doi-asserted-by":"crossref","unstructured":"Crino SF et al (2023) Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clin Gastroenterol Hepatol 21(11):2834-2843","DOI":"10.1016\/j.cgh.2023.02.022"},{"issue":"7","key":"1734_CR12","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel\u00a0M et\u00a0al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(7):844\u2013860","journal-title":"Ann Oncol"},{"issue":"e13343","key":"1734_CR13","first-page":"12","volume":"35","author":"B Kos-Kudla","year":"2023","unstructured":"Kos-Kudla\u00a0B et\u00a0al (2023) European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J\u00a0Neuroendocrinol 35 (12): e13343","journal-title":"J Neuroendocrinol"},{"key":"1734_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.033","volume":"175","author":"C Lepage","year":"2022","unstructured":"Lepage\u00a0C et\u00a0al (2022) Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase\u00a0II trial\u2014Prodige 31 REMINET: An FFCD study. Eur J Cancer 175:31\u201340","journal-title":"Eur J Cancer"},{"key":"1734_CR15","doi-asserted-by":"crossref","unstructured":"Salazar R. et al (2022) Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206). Ann Oncol Volume 33, Suppl 7, S1412. DOI: https:\/\/doi.org\/10.1016\/j.annonc.2022.08.044","DOI":"10.1016\/j.annonc.2022.08.044"},{"issue":"1","key":"1734_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-021-02859-y","volume":"75","author":"H Lahner","year":"2022","unstructured":"Lahner\u00a0H et\u00a0al (2022) Streptozocin\/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine 75(1):293\u2013302","journal-title":"Endocrine"},{"issue":"7","key":"1734_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz\u00a0PL et\u00a0al (2023) Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J\u00a0Clin Oncol 41(7):1359\u20131369","journal-title":"J Clin Oncol"},{"key":"1734_CR18","doi-asserted-by":"crossref","unstructured":"Pavel M et al (2024) Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. Oncologist 29(5):e643-e654","DOI":"10.1093\/oncolo\/oyad325"},{"issue":"6","key":"1734_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1159\/000518650","volume":"112","author":"P Girot","year":"2022","unstructured":"Girot\u00a0P et\u00a0al (2022) Oxaliplatin and 5\u2011Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A\u00a0Multicenter National Retrospective Study from the French Group of Endocrine Tumors. Neuroendocrinology 112(6):537\u2013546","journal-title":"Neuroendocrinology"},{"issue":"20","key":"1734_CR20","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1200\/JCO.20.03368","volume":"39","author":"J Capdevila","year":"2021","unstructured":"Capdevila\u00a0J et\u00a0al (2021) Lenvatinib in Patients With Advanced Grade\u00a01\/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase\u00a0II TALENT Trial (GETNE1509). J\u00a0Clin Oncol 39(20):2304\u20132312","journal-title":"J Clin Oncol"},{"key":"1734_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.annonc.2023.10.047","volume":"34","author":"J Chan","year":"2023","unstructured":"Chan\u00a0J et\u00a0al (2023) Alliance A021602: Phase\u00a0III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann Oncol 34(Suppl_2):S1292","journal-title":"Ann Oncol"},{"key":"1734_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2021.39.3_suppl.360","volume":"39","author":"R Garcia-Carbonero","year":"2021","unstructured":"Garcia-Carbonero\u00a0R et\u00a0al (2021) A\u00a0phase\u00a0II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1\u2013G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). J Clin Oncol Volume 39 (3) suppl; https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.360","journal-title":"JCO"},{"issue":"22","key":"1734_CR23","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch\u00a0E et\u00a0al (2021) Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N\u00a0Engl J Med 385(22):2036\u20132046","journal-title":"N Engl J Med"},{"key":"1734_CR24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.annonc.2022.08.074","volume":"33","author":"R Srinivasan","year":"2022","unstructured":"Srinivasan\u00a0R et\u00a0al (2022) Belzutifan, a HIF-2\u03b1 Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase\u00a0II LITESPARK-004 study. Ann Oncol 33, Suppl 7:1433; https:\/\/doi.org\/10.1016\/j.annonc.2022.08.074","journal-title":"Ann Oncol"},{"key":"1734_CR25","doi-asserted-by":"crossref","unstructured":"Singh et al (2024) [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. Jun 5:S0140-6736(24)00701-3.","DOI":"10.1016\/S0140-6736(24)00701-3"},{"key":"1734_CR26","doi-asserted-by":"publisher","unstructured":"Halfdanarson TR et al (2022) Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors. J Clin Oncol 40(4) Suppl https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.TPS51","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS51"},{"key":"1734_CR27","doi-asserted-by":"publisher","unstructured":"Baudin\u00a0E. et al (2022) First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium\u2014DOTA-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial. Ann Oncol 33(7):410 https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1013","DOI":"10.1016\/j.annonc.2022.07.1013"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01734-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01734-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01734-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:03:58Z","timestamp":1719385438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01734-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01734-y","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"27 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Pavel hat Honorare erhalten f\u00fcr Beratert\u00e4tigkeit und\/ oder Vortr\u00e4ge von\nIPSEN, Novartis, AAA, ITM, Recordati, Serb, Sanofi, Lilly, MSD, Boehringer-Ingelheim. H.\u00a0Lahner hat Honorare erhalten f\u00fcr Beratert\u00e4tigkeit und\/ oder Vortr\u00e4ge von IPSEN, Novartis, AAA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}